OR WAIT null SECS
October 02, 2020
Cellular and gene therapy fields are currently on track for, if not already experiencing, a serious capacity crunch.
September 30, 2020
Cellnest will join Fujifilm Irvine Scientific’s PRIME-XV portfolio which consists of xeno-free and chemically defined media for stem cell culture.
September 21, 2020
Catalent will use T-knife´s TCR platform for a T-cell receptor-based cell therapy at its Gosselies, Belgium, site in order to manufacture clinical batches for European trials in 2021.
September 17, 2020
The new facility will produce cell therapies for clinical evaluation from discovery through to Phase 2b trials while expanding Takeda’s abilities to develop next-generation cell therapies.
September 14, 2020
The investment will include new manufacturing lines and increased automation to deliver additional manufacturing capacity.
August 07, 2020
The European Medicines Agency recently approved two European Novartis sites in France and Switzerland for the commercial manufacturing of chimeric antigen receptor T-cell cell therapies.
August 02, 2020
The early success seen on the market for approved cell and gene therapies poses both technical and manufacturing challenges for pipeline candidates on the road to commercialization.
July 02, 2020
Manufacturers must address scale-out challenges of autologous cell therapy for commercial manufacturing.
June 30, 2020
The site can now support customized product and bioprocess development and custom cell and gene therapy reagent manufacturing.
June 22, 2020
The company will invest $75 million into its Canton, MA, facility to expand its viral vector, gene therapy, and contract development and manufacturing capabilities.